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Abstract
Background: Despite evidence supporting the safety of vaginal birth after caesarean section (VBAC), rates are low
in many countries.
Methods: OptiBIRTH investigated the effects of a woman-centred intervention designed to increase VBAC rates
through an unblinded cluster randomised trial in 15 maternity units with VBAC rates < 35% in Germany, Ireland and
Italy. Sites were matched in pairs or triplets based on annual birth numbers and VBAC rate, and randomised, 1:1 or
2:1, intervention versus control, following trial registration. The intervention involved evidence-based education of
clinicians and women with one previous caesarean section (CS), appointment of opinion leaders, audit/peer review,
and joint discussions by women and clinicians. Control sites provided usual care. Primary outcome was annual
hospital-level VBAC rates before the trial (2012) versus final year of the trial (2016). Between April 2014 and October
2015, 2002 women were recruited (intervention 1195, control 807), with mode-of-birth data available for 1940
women.
Results: The OptiBIRTH intervention was feasible and safe across hospital settings in three countries. There was no
statistically significant difference in the change in the proportion of women having a VBAC between intervention
sites (25.6% in 2012 to 25.1% in 2016) and control sites (18.3 to 22.3%) (odds ratio adjusted for differences between
intervention and control groups (2012) and for homogeneity in VBAC rates at sites in the countries: 0.87, 95% CI:
0.67, 1.14, p = 0.32 based on 5674 women (2012) and 5284 (2016) with outcome data. Among recruited women
with birth data, 4/1147 perinatal deaths > 24 weeks gestation occurred in the intervention group (0.34%) and 4/782
in the control group (0.51%), and two uterine ruptures (one per group), a rate of 1:1000.
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Conclusions: Changing clinical practice takes time. As elective repeat CS is the most common reason for CS in
multiparous women, interventions that are feasible and safe and that have been shown to lead to decreasing
repeat CS, should be promoted. Continued research to refine the best way of promoting VBAC is essential. This
may best be done using an implementation science approach that can modify evidence-based interventions in
response to changing clinical circumstances.
Trial registration: The OptiBIRTH trial was registered on 3/4/2013. Trial registration number ISRCTN10612254.
Background
Rates of caesarean sections (CSs) are increasing, yet de-
creases in maternal and perinatal mortality are not seen
when more than 10% of births in a population are by CS
[1]. Between 1990 and 2014, average CS rates increased
from 6.7 to 19.1% globally, and from 11.2 to 25% across
Europe [2]. In 2010, CS rates in 31 countries and regions
in Europe ranged from 14.8% in Iceland to 52.2% in
Cyprus [3] with highest rates among women who had
had a previous CS [3]. These were between 45 and 55%
in the Netherlands, Norway, Finland and Iceland, 64% in
Germany, approximately 90% in Italy, and not reported
in several countries, including Ireland. Similarly, CS
rates in Australia ranged from 11.8 to 47.4% across 81
hospitals [4] with rates of 82.1% among 61,894 materni-
ties with a previous CS [5]. Less than half (49%) of the
variation in repeat CS rates in the latter study was ex-
plained by differences in women’s characteristics and
hospital practices, indicating the association of other,
non-clinical, factors [5]. A recent systematic review by
the World Health Organization shows that 106 out of
169 countries have CS rates greater than the 9 to 16%
level above which no decrease in maternal or neonatal
mortality is seen [6]. CS rates exceed 40% in some coun-
tries, including the Dominican Republic (59%), Brazil
(56%), Egypt (63%), and Turkey (53.1%) [7]. Given the
short and long-term adverse effects of CS, these rates
cause concern [8].
Elective repeat CS (ERCS) and planned vaginal birth
after CS (VBAC) for women with a prior CS are both as-
sociated with benefits and harms [9]. Most studies report
an increase in adverse maternal and neonatal outcomes
following repeat CS [10–12]. The findings of one sys-
tematic review reported that maternal mortality is de-
creased by planned VBAC compared with ERCS, with
nine fewer deaths per 100,000 women [13]. Significant
increases in perinatal mortality were seen for “trial of
labour” (0.13% compared with 0.05% for ERCS), but the
authors concluded that, as the absolute risk of perinatal
death is low, the evidence suggested that VBAC was a
reasonable choice for the majority of women [13].
In response to rising CS rates in the United States,
the National Institutes for Health and the American
College of Obstetricians and Gynaecologists (ACOG)
issued guidelines recommending “trial of labour after
CS”, as they termed it, in 2010 [14, 15]. Two years later,
44% of hospitals in California still did not permit
planned VBAC, and one tenth of the 56% of hospitals
that did allow planned VBAC reported that fewer than
3% of women who had had a previous CS had a vaginal
birth [16]. This indicates how difficult it can be, and
how long it can take, to change clinicians’ opinion and
by doing so, impact on women’s self-determined prefer-
ences to have a VBAC.
Findings from a recent systematic review of clinician-
focussed interventions showed that the only strategy that
significantly increased VBAC rates was an educational
intervention provided by an opinion leader [17]. A study
of 44 clinicians practising in three countries with high
VBAC rates (> 45%) [18], and a similar study based on
71 clinicians from countries with low VBAC rates [19]
showed comparable findings related to trust in the
clinician-woman relationship, a positive attitude of all
centrally involved, early follow-up and fear reduction.
However, differences shown related to the decision-
making process, parameters for VBAC, organisational
support and resources, and clinical expertise, which indi-
cate different attitudes and views among clinicians in
countries with high and low VBAC rates.
Information sessions and decision-aids for women
during pregnancy did not increase VBAC but did signifi-
cantly decrease their decisional conflict and increase
their knowledge of mode of birth [20]. Therefore, the
promotion of VBAC requires the provision of evidence-
based information to women on the benefits and limita-
tions of VBAC [21] and the options open to them [22].
The need to provide better information for women and
to improve VBAC rates led to the development of the
OptiBIRTH intervention, which has been compared with
usual care for women with one previous CS in this clus-
ter randomised trial in Germany, Ireland and Italy [23].
Registration
The OptiBIRTH trial was prospectively registered in the
ISRCTN Registry before randomisation of the clusters (ma-
ternity units) to intervention or control (ISRCTN10612254),
and the protocol was published [23].
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Methods
Study design
A cluster randomised trial of 15 small, medium and
large maternity units (annual births of 1800 to 8500) in
both urban and rural locations in Germany, Ireland and
Italy, with VBAC rates of 35% or less. Five maternity
units took part in each country, with the 2 units in
Hannover (Germany) being allocated to the same group
to avoid having an intervention and a control site in the
same city. A sixth German maternity unit was with-
drawn from the trial following recruitment of only three
participants during the pilot phase. The pilot study was
conducted in 2014 from January to April (Germany),
February to March (Ireland) and February to April
(Italy). Minimal changes were made to data collection,
selection, enrolment processes and the length of the
clinician information session during the pilot phase but,
as planned, the main trial results (presented in this
paper) exclude women recruited during the pilot study.
Randomisation and blinding
The unit of randomisation was the maternity unit (the
“site”). Primary analyses considered women’s data at the
level of each site as a whole, rather than at the level of
women recruited. This was decided in order to investi-
gate the effects of the OptiBIRTH intervention on a cul-
tural change in practice, affecting the care of all women
with one previous CS at the site, regardless of whether
or not they were recruited to the trial. Random alloca-
tion of sites to intervention or control was carried out in
advance of approaching women to participate. The ma-
ternity units that had agreed to join the trial were
matched by their annual number of births and then by
VBAC rate in each country, in either pairs or triplets.
They were then randomised 1:1 or 2:1 to intervention or
control, respectively [23]. This resulted in six rando-
mised comparisons. Blinding of clinicians and participat-
ing women was not possible because they were part of
the intervention. However, the trial team were blinded
to the results of the trial until recruitment was closed
and the data analyses completed.
Eligibility
Pregnant women at a participating site who were: aged
18 years of age or over at time of booking; had one pre-
vious lower segment CS (not a classical/high vertical in-
cision); spoke the language of the country where they
were recruited (German, English or Italian); and gave
written informed consent to participate.
Pregnant women with known multiple pregnancy at
time of booking were ineligible. (As noted in the results,
one woman was recruited and subsequently found to be
pregnant with twins.)
Interventions
Sites randomised to the intervention group received a
complex, innovative programme of evidence-based ante-
natal strategies, developed following three systematic re-
views [17, 20, 21], and four qualitative studies with
clinicians and women in both high and low VBAC coun-
tries [18, 19, 24, 25]. Technology-assisted learning re-
sources were also developed using motivational systems
and instructional design theory [26]. The intervention
involved the provision of evidence-based education for
women (two antenatal classes), clinicians (one-hour ses-
sion), access to optional online educational resources
and mobile/computer applications, introduction of com-
munities of practice (women and clinicians sharing
knowledge), appointment of midwife and obstetric opin-
ion leaders, audit and peer review of CS rates in each
site, and joint discussion by women and clinicians. In
each site, the intervention was delivered by the midwife
and obstetric ‘opinion leaders,’ supported by researchers
from the OptiBIRTH team.
A checklist was developed to assess, monitor and
evaluate adherence to the intervention in each site, and
was applied twice, once during the pilot phase and once
during the main trial. Details of the attendance of clini-
cians at educational sessions, and women at the ante-
natal classes, the use of online resources and adherence
to the intervention were monitored during the trial, in
each intervention site [27]. Sites randomised to the con-
trol group followed the usual practice for that unit.
Data collection for recruited women
Women in each site were screened for eligibility for
OptiBIRTH at their first visit, using a pre-designed Trial
Screening and Register Form. Women judged eligible
were informed of the study verbally and received a study
pack, which included a detailed information leaflet and
consent form. On receipt of the signed consent form,
women were contacted by the midwife opinion lead
(MOL) for the site and provided with further details on
accessing the trial processes (intervention sites only). Al-
though all eligible women could be considered to have
been randomised and we used site-level routine data for
the primary analyses (see below), individual data could
only be used for women who gave their consent. As is
expected in an unblinded cluster randomised trial, this
can lead to differences between the women who joined
the trial in the intervention and control sites, the impact
of which is considered through adjusted analyses below.
Women gave their consent to participate in the trial at
one of two levels:
1. Full participation: if they were in an intervention
site and wanted to attend the OptiBIRTH antenatal
classes and, if desired, access the online resources.
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In both intervention and control sites, a woman
choosing full participation agreed to complete
health surveys and a diary recording her expenses
for healthcare services used, and gave us permission
to access the healthcare records for herself and her
baby.
2. Routine data only: this gave us permission to access
the personal healthcare records for the woman and
her baby. In the intervention sites, these women
preferred not to attend the antenatal classes or access
the online resources and, in both intervention and
control sites, they did not wish to complete the
health surveys and diary of healthcare expenses.
Ethical approval was granted by the Faculty of Health
Sciences, Trinity College Dublin, Ireland and Research
Ethics Committees for all participating sites in each
country (Additional file 1).
All outcome data on recruited women were collected
using pre-designed data forms. These included self-report
of antenatal and postnatal health and healthcare resource
use and expenditure surveys, and clinician-reported labour
and birth outcome data. Data from hospital records of
participating women were collected at each site by the
MOL and submitted to the trial and data management
centre encrypted. To identify and exclude errors, each
country’s researchers checked 5 to 10% of the data col-
lected and entered, every quarter. For the hospital-level
data, the annual statistics for each site were checked to ex-
tract the mode of birth for all eligible women who gave
birth at that site in the year before the trial (2012) and in
the final year of the trial (2016), This paper reports the
analyses for these routinely collected data on labour and
birth. Subsequent papers will report analyses of the data
collected via the antenatal and postnatal questionnaires,
including economic analyses of resource use.
Outcome measures
Primary outcome for site-level data
The pre-specified primary outcome for the trial is the pro-
portion of women with one previous CS who have a vaginal
birth in each site comparing the calendar year before the
trial (2012) versus the final year of the trial (2016) to assess
the sustainability of any intervention effect at site level.
Secondary outcomes for recruited women, presented in this
paper
Maternal outcomes, collected at or shortly after birth,
are:
 Labour onset (spontaneous, induced, etc.)
 Acceleration of labour (artificial rupture of
membranes, oxytocin use)
 Mode of birth
Neonatal outcomes, collected during pregnancy and
at, or shortly after, birth are:
 Fetal demise during pregnancy (miscarriage or
intrauterine death after 24 weeks gestation)
 Gestational age at birth
 Admission to neonatal intensive care unit (NICU)
 Neonatal mortality
Additional secondary outcomes (health economics,
quality of life) will be presented in subsequent papers, in
accordance with the published protocol [23].
Sample size assumptions and estimates
We performed a sample size calculation to estimate the
number of women who would need to be recruited in
each site to detect the desired effect on VBAC (primary
outcome) and to provide data on other antenatal and
postnatal factors and outcomes. This sample size would
be smaller than that available from routine data – i.e.,
the number of women with one previous CS who would
give birth in each site in the year prior to the trial, and
the final year of the trial, to be used for the primary out-
come analysis. To allow for clustering, an estimate of the
sample size for an individually randomised trial was ad-
justed and inflated by the design effect given by 1 + (ñ-1)
ρ, where ñ was the average cluster size and ρ was the es-
timated intra-class correlation coefficient (ICC) for this
study. This sample size calculation used a background
proportion of successful VBAC of 25% and an ICC of
0.05. It showed that 12 sites would be required, each
containing 120 participating women (840 women in the
intervention group and 840 women in the control
group), to detect a 15-percentage point difference in suc-
cessful VBAC (i.e. an absolute increase from 25% in the
control group to 40% in the intervention group), with
power of at least 80% and an alpha level of 0.05. If the
true ICC values are less than 0.05, the power of the
study will increase. To allow for a loss to follow-up of
up to 20% of women and the possibility that one site per
country would drop out of the trial, 16 maternity units
were randomised.
Data analysis
The primary analysis was to test the effect of Opti-
BIRTH at site level by comparing VBAC proportions in
the intervention and control sites in the calendar year
2016, while adjusting for differences between countries
and sites at baseline (i.e., during 2012) and for clustering
due to intervention allocation at the site level. The first
analysis compared the difference in VBAC proportions
aggregated at the site level, and the second analysis com-
pared the difference in VBAC proportions at the individ-
ual level. A generalised linear mixed model for a binary
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response was used for both analyses to model the effect
of treatment allocation (i.e. OptiBIRTH intervention ver-
sus control), adjusting for baseline VBAC proportion at
site level and country of the site, with random intercepts
included to account for the variability due to clustering
by site. When modelling the data available from those
women who participated in OptiBIRTH, we also report
results from a generalised linear mixed model with ad-
justment for baseline VBAC proportion at site level,
baseline characteristics of mother’s body mass index (kg/
m2), age (years), previous vaginal birth before caesarean
(yes/no), previous VBAC (yes/no) and gestational age of
infant (weeks) with random effects for site and country.
Odds ratios (OR) and corresponding 95% confidence
intervals (CI) and p-values are reported. All analyses
were carried out using R version 3.1 and the lme4 pack-
age [28] for generalised linear mixed effects models.
We also analysed data for the women who agreed to
take part in the trial and their babies, to assess the effects
of the intervention on the secondary outcomes listed
above. These were done as fixed-effect meta-analyses of
the six randomised comparisons of the sites without
adjustment for baseline characteristics, with a sensitivity
analysis using the random effects model. They included
pre-specified subgroup analyses for (1) whether the
woman had had a vaginal birth before her previous CS
(yes, no), (2) whether the woman had had a vaginal birth
between her previous CS and her current pregnancy (yes,
no), (3) age at baseline (< 40 years, ≥40 years), (4) body
mass index (BMI) at baseline (< 25 kg/m2, 25–29.99 kg/
m2, ≥30 kg/m2), and (5) gestational age at baseline (< 30
weeks, 30–32 weeks, ≥33 weeks). Women recruited at ≥33
weeks gestation were categorised as “late” recruits who we
assumed might benefit less from the intervention than
those who were recruited earlier (< 33 weeks gestation),
because of the shorter exposure to the intervention or less
opportunity to influence decisions about VBAC. To assess
the potential impact of baseline imbalances in this un-
blinded, cluster randomised trial, sensitivity analyses were
done for the overall results for recruited women, in which
adjustments were made for baseline characteristics: (1) (2)
(4) and (5) above.
Data monitoring committee
In May 2015, a Data Monitoring Committee (DMC)
conducted an interim analysis of data from 700 women
who had birthed at that point. The DMC were provided
with unblinded data on the VBAC rate at each site in
the year before the trial began, the number of women re-
cruited in each site and the proportion of those who had
birthed vaginally. Based on the evidence presented at
that time, the DMC recommended that the trial should
continue.
Role of the funding source
The funding body had no input into study design, data
collection, analysis, and interpretation, the writing of the
report or the decision to submit the paper for publication.
Recruitment to the main trial
Women were recruited to the main OptiBIRTH trial from
1 April 2014 in Ireland (n = 622) and from 1 May 2014 in
Germany (n = 755) and Italy (n = 625). Most sites closed
when they reached their target of 120 participants, during
March to May 2015. Formal closure of recruitment was
on 31 October 2015. The data set was closed for the pur-
poses of this paper on 9 March 2018. Across the 15 sites,
5674 women (intervention: 2518; control: 3156) who had
had one previous CS birthed in 2012, compared to 5284
women (intervention: 2432; control: 2852) in 2016. In the
main trial, 2002 women were recruited across the 15 sites
in the three countries (Fig. 1).
A total of 1831 women agreed to full participation
(intervention: 1073; control: 758), and a further 171
agreed to partial participation (allowing use of their
birthing data only) (intervention: 122; control: 49). Base-
line data were available on all 2002 women (intervention:
1195; control: 807) who had agreed to take part and
some birthing data were available for 1956 (97.7%)
(intervention: 1174 (98.2%); control: 782 (96.9%)) of
these (Additional files 2, 3, 4).
Table 1 shows that there were statistically significant
imbalances between the intervention and control groups
for women who had VBAC between their previous CS
and their OptiBIRTH pregnancy in Italy, and gestational
age at recruitment in Germany. Our adjusted analyses
investigate the effect of all imbalances in baseline vari-
ables on the findings of the trial, regardless of the statis-
tical significance of the imbalance.
Results
The results comparing the effect of OptiBIRTH are pre-
sented initially for site-level comparisons followed by
comparisons using individual-level data.
Analysis at site level
The changes in VBAC proportion for each allocation
group over time overall, by country, are given in Table 2
and Fig. 2, while a breakdown by site is given in Table 3.
There was a 4.02% increase in VBAC proportions among
control sites while there was a 0.5% decrease among
OptiBIRTH sites between 2012 and 2016.
There were decreases in VBAC proportions in both
control (1.39%) and intervention (6.53%) sites in Ireland,
and increases in both control (10.71%) and intervention
(11.29%) sites in Italy (i.e. intervention sites had better
improvements than control in Italy). The largest im-
provement and reduction in VBAC proportions occurred
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in intervention sites, with a 21.64% increase in Italy (Site
13) and an 8.9% decrease in Germany (Site 3) (Table 3).
Overall, the adjusted analyses (Table 4) showed no evi-
dence of a significant intervention effect while adjusting
for differences between the intervention and control
groups at baseline (year 2012) due to randomisation at site
level and for homogeneity in the VBAC rates at sites in
countries (odds ratio: 0.87, 95% CI: 0.67, 1.14, p = 0.32).
There was evidence that the proportion of VBAC in
2012 was a useful predictor of VBAC proportions in
2016 (odds ratio: 1.04, 95% CI: 1.02, 1.06, p < 0.001), a
possible higher odds of VBAC in Italy compared to
Ireland (odds ratio: 1.44, 95% CI: 0.98, 2.12, p = 0.06), no
evidence of a significant difference between Ireland and
Germany (odds ratio = 1.09, 95% CI: 0.85, 1.39, p = 0.49)
and between Italy and Germany (odds ratio = 0.32, 95%
CI: 0.85, 2.04, p = 0.21). The intracluster correlation due
to clustering at the site level was estimated to be 0.006.
Analysis at individual level
There was no evidence of a significant OptiBIRTH effect
(OR 1.09, 95% CI 0.76 to 1.56; p = 0.66) after adjustment
for covariates (Table 5) based on the analysis of the indi-
vidual level data from the 1956 full participants. The odds
of having a VBAC decreased with increasing BMI (OR
0.94, 95% CI 0.92 to 0.96; p < 0.001) and increased with
increasing gestational age at birth (OR 1.02, 95% CI 1.01
to 1.03; p = 0.02). Neither a mother’s age nor proportion
of VBAC in 2012 were useful predictors of VBAC propor-
tions in 2016 when adjusting for baseline covariates.
Having had a previous VBAC significantly increased the
odds of a subsequent VBAC (OR 0.42, 95% CI 0.30 to
0.60; p < 0.001), while having had a vaginal birth before a
CS significantly decreased the odds of a subsequent VBAC
(OR 7.18, 95% CI 4.41 to 11.69; p < 0.001). Italy had a
lower VBAC proportion than Ireland (OR 0.6, 95% CI
0.36 to 1.01; p = 0.05), while Germany had a higher pro-
portion (OR 1.56, 95% CI 1.11 to 2.2; p = 0.01) than
Ireland.
Birth outcomes, using data for recruited women
Mode of birth Table 6 shows the mode of birth for
women who agreed to join the trial in each of the coun-
tries and for the trial overall. No birth data are available
for 46 of the 2002 recruited women (for example, because
they moved to a different area or gave birth elsewhere),
and mode of birth is not available for a further 16 women
who had a miscarriage/intrauterine death at less than 24
weeks gestation (n = 8) or more than 24 weeks (3) or for
whom the mode of birth was missing at the time of data
lockdown (5). Therefore, of the 1940 recruited women
with known mode of birth, 385 (33.0% of 1165) in the
intervention group and 223 (28.8% of 775) in the control
group had a VBAC, but there is substantial statistical het-
erogeneity across the six randomised comparisons (Fig. 3).
There is a statistically significant relative increase in
VBAC of 16% for the intervention group compared to
the control group (risk ratio (RR): 1.16; 95% CI: 1.01 to
1.33; p = 0.03), with an absolute increase of 5% (95% CI:
Fig. 1 Flow diagram for recruited participants
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0 to 9%) for the intervention group compared to the
control group. However, when this analysis is adjusted
for the baseline characteristics, the difference becomes
non-significant. It is also not significant if the random
effects model is used for the meta-analysis (RR: 1.19;
95% CI: 0.88 to 1.62; p = 0.28).
Onset of labour Of the 1956 women for whom some
birth data are available, onset of labour was spontaneous
in 445 (37.9% of 1174) in the intervention group and 281
(35.9% of 782) in the control (RR: 1.07; 95% CI: 0.95 to
1.21; p = 0.25), a non-significant difference. Labour was
induced for 82 women (10.5%) in the intervention group
Table 1 Baseline characteristics of all women recruited to the trial
Characteristic Maternity unit or country
(number of recruited
women)
Intervention sites Control sites Odds ratio [95% CI] or
Mean Difference [95% CI]
Number recruited Trial as a whole 1195 807
Germany 466 289
Ireland 368 254
Italy 361 264
Any prior vaginal birth (before previous CS) Trial as a whole 104 (8.7%) 54 (6.7%) 1.30 [0.92, 1.83]
Germany 28 (6.0%) 16 (5.5%) 0.91 [0.48, 1.74]
Ireland 58 (15.8%) 30 (11.8%) 1.37 [0.86, 2.18]
Italy 18 (5.0%) 8 (3.0%) 1.94 [0.83, 4.56]
Any prior VBAC Trial as a whole 75 (6.3%) 32 (4.0%) 1.52 [0.99, 2.33]
Germany 26 (5.6%) 18 (6.2%) 0.91 [0.48, 1.71]
Ireland 32 (8.7%) 13 (5.1%) 1.56 [0.80, 3.06]
Italy 17 (4.7%) 1 (0.4%) 8.94 [1.62, 49.27]
Gestational age at recruitment (mean, weeks)a Trial as a whole 26.3 (9.4) 24.8 (10.5) 1.15 [0.42, 1.88]
Germany 32.7 (5.6) 28.3 (11.4) 4.40 [2.99, 5.81]
Ireland 19.6 (7.3) 19.1 (5.3) 0.50 [−0.49, 1.49]
Italy 24.8 (9.8) 26.4 (11.1) −1.60 [−3.28, 0.08]
BMI at recruitment (mean)b Trial as a whole 25.8 (5.1) 27.0 (5.5) −1.26 [− 1.73, −0.79]
Germany 25.6 (5.5) 26.2 (5.3) −0.60 [−1.39, 0.19]
Ireland 26.6 (4.9) 27.2 (5.8) −0.60 [−1.47, 0.27]
Italy 25.2 (4.8) 27.7 (5.2) −2.50 [−3.30, −1.70]
Age at recruitment (mean, years)c Trial as a whole 34.0 (4.5) 34.2 (4.7) −0.27 [− 0.67, 0.14]
Germany 34.1 (4.3) 33.8 (4.7) 0.30 [−0.37, 0.97]
Ireland 33.0 (4.2) 33.5 (4.4) −0.50 [−1.19, 0.19]
Italy 34.8 (4.8) 35.5 (4.6) −0.70 [−1.44, 0.04]
a. Gestational age at baseline is missing for 4 women (intervention: 2; control: 2)
b. BMI at baseline is missing for 139 women (intervention: 86; control: 53)
c. Age at baseline is missing for 4 women (intervention: 0; control: 4)
Table 2 VBAC change from 2012 to 2016 by allocation and country
Country Allocation Births ‘12 (n) VBAC ‘12 (n) VBAC ‘12 (%) Births ‘16 (n) VBAC ‘16 (n) VBAC ‘16 (%) VBAC (% improvement)
Control 3156 576 18.25 2852 635 22.27 4.02
Intervention 2518 645 25.62 2432 611 25.12 −0.50
Germany Control 473 129 27.27 585 159 27.18 −0.09
Intervention 733 247 33.70 1030 281 27.28 −6.42
Ireland Control 1408 312 22.16 1281 266 20.77 −1.39
Intervention 1049 337 32.13 922 236 25.60 −6.53
Italy Control 1275 135 10.59 986 210 21.30 10.71
Intervention 736 61 8.29 480 94 19.58 11.29
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and 49 (6.2%) in the control. The remaining women had
CS without going into labour, 647 (55.1%) in the interven-
tion group and 452 (57.8%) in the control group.
Of the 857 women who laboured (for all of whom we
have birth data), labour onset was spontaneous in 445
(84.4% of 527) in the intervention group and 281 (85.2%
of 330) in the control (Table 7) (RR: 0.99; 95% CI: 0.93 to
1.05; p = 0.62), a non-significant difference. Labour was
induced for the other 82 (15.6%) in the intervention group
and 49 (14.8%) in the control group who laboured.
Of the 857 women who laboured, labour was acceler-
ated in 226 women (42.9% of 527) in the intervention
group and 146 (44.2% of 330) in the control group (RR:
0.99; 95% CI: 0.85 to 1.16; p = 0.88), a non-significant
difference.
Uterine rupture Data on all reported uterine ruptures
were reviewed, to distinguish between scar dehiscence and
full uterine rupture; there were two full uterine ruptures in
the main trial (one in each group), one following an induced
labour, the other spontaneous. Both women and babies
were discharged home well by day 5 and day 4, respectively.
Subgroup analyses for maternal outcomes Caution is
needed in the interpretation of subgroup analyses, when
the overall result is not statistically significant [29, 30].
Fig. 2 Changes in site-level VBAC rates for 2012 compared to 2015, within countries and overall (adjusted)
Table 3 Change in VBAC proportion from 2012 to 2016 by Country and site
Country Allocation Site Births 2012
(n)
VBAC 2012
(n)
VBAC 2012
(%)
Births 2016
(n)
VBAC 2016
(n)
VBAC 2016
(%)
VBAC (%
improvement)
Germany Control 1 284 73 25.70 365 81 22.19 −3.51
2 189 56 29.63 220 78 35.45 5.82
Intervention 3 288 99 34.38 420 107 25.48 −8.90
4 445 148 33.26 610 174 28.52 −4.73
Ireland Control 5 889 192 21.60 861 186 21.60 0.01
6 519 120 23.12 420 80 19.05 −4.07
Intervention 7 279 104 37.28 214 63 29.44 −7.84
8 547 153 27.97 549 122 22.22 −5.75
9 223 80 35.87 159 51 32.08 −3.80
Italy Control 10 224 4 1.79 233 24 10.30 8.51
11 1051 131 12.46 753 186 24.70 12.24
Intervention 12 77 26 33.77 112 32 28.57 −5.19
13 212 11 5.19 82 22 26.83 21.64
14 447 24 5.37 286 40 13.99 8.62
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However, for completeness, Table 8 presents the main
maternal outcomes within the pre-specified subgroups.
This shows variable effects in different subgroups. How-
ever, given the number of such analyses, the relatively
small number of women in some subgroups, and the
challenges of recruiting participants in a cluster rando-
mised trial when the allocation cannot be concealed,
there is no strong evidence of clear benefit or harm for
the OptiBIRTH intervention in any of the subgroups.
Given the possibility that women who were recruited
late to the trial (at or beyond week 33 of their preg-
nancy) might lead to an underestimate of any effect of
the intervention, a sensitivity analysis was done exclud-
ing such women. This found a RR of 1.08 (95% CI: 0.88
to 1.31, p = 0.46) for VBAC comparing the intervention
and control groups.
Antenatal and neonatal outcomes, using data for recruited
women
Table 9 shows neonatal outcomes for women who agreed
to join the trial. These data use the birth data that are
available for 1956 (97.7%) of the 2002 recruited women.
A total of 16 pregnancies (intervention: 11; control: 5)
ended in intrauterine death, 10 before 24 weeks’ gesta-
tion (intervention: 7; control: 3) and six after (interven-
tion: 4; control: 2). Taken separately, or combined, there
was no significant difference in these deaths between the
intervention and control groups. Two of the recruited
women experienced a neonatal death, both in the con-
trol group, giving total perinatal death figures, after 24
weeks gestation, of four out of 1174 (0.34%) for whom
some birth data are available in the intervention group
and four out of 782 in the control (0.51%).
Of the 1940 babies born alive (and for whom we have
birth data, excluding the second twin born to a woman in
the control group), 62 babies (5.3% of 1163) in the inter-
vention group were born before 37 weeks gestation, com-
pared to 50 (6.4% of 777) in the control group (Table 6)
(RR: 0.81; 95% CI: 0.56 to 1.17; p = 0.26), a non-
statistically significant difference (95% CI: − 3 to 1%).
Similarly, there was little difference in mean gestational
age at birth between babies in the intervention (mean:
38.9 weeks; SD: 1.5) and control (mean: 38.7 weeks; SD:
1.8) groups. This difference of approximately 1 day is of
borderline statistical significance in the unadjusted ana-
lysis (95% CI: 0.07 weeks to 0.28 weeks; p = 0.05).
Of the 1163 live-born babies in the intervention group
for whom data are available, 90 (7.7%) were admitted to
NICU compared to 63 (8.1% of 777) in the control
(Table 6) (RR: 0.87; 95% CI: 0.64 to 1.17; p = 0.36), a
non-significant difference.
Subgroup analyses for neonatal outcomes
For most neonatal outcomes, the small number of events
does not warrant dividing the analyses into subgroups
using baseline characteristics of the mothers. However,
Table 10 shows these subgroup analyses for three out-
comes: birth before 37 weeks, gestational age at birth
and admission to NICU. As with the subgroup analyses
for maternal labour and birth outcomes (Table 8), this
shows variable effects in different subgroups, but with-
out any strong evidence of clear benefit or harm for the
OptiBIRTH intervention for the babies based on any of
the subgroups.
Discussion
We have demonstrated through this cluster randomised
trial that, in these hospital settings in three countries,
the OptiBIRTH intervention is feasible and safe. Overall,
in this analysis we found no statistically significant dif-
ference in the change in the proportion of women hav-
ing a VBAC between the intervention sites (25.6% in
2012 to 25.1% in 2016) and the control sites (18.3% in
2012 to 22.3% in 2016). Change in clinical practice is no-
toriously slow [31], and both clinicians and women need
time to become accustomed to new approaches to care.
In particular, complex interventions such as that devel-
oped for OptiBIRTH require the passage of time and a
willingness to engage with them to ensure uptake. A
continuance of slow change over the next few years,
Table 5 Logistic model of VBAC in 2016 for n = 1956 with
covariate data available, adjusted for 2012 VBAC rate and
covariates with random intercept for site
Odds Ratio 95% CI p-value
OptiBIRTH 1.09 0.76, 1.56 0.66
VBAC 2012 (%) 1.00 0.97, 1.02 0.76
BMI (kg/m2) 0.94 0.92, 0.96 < 0.001
Age (years) 0.99 0.96, 1.01 0.24
Gestational Age (weeks) 1.02 1.01, 1.03 0.02
VB before CS 0.42 0.30, 0.60 < 0.001
Previous VBAC 7.18 4.41, 11.69 < 0.001
Germany v Ireland 1.43 0.96, 2.12 0.08
Italy v Ireland 0.58 0.34, 1 0.05
Table 4 Generalised mixed effect logistic model adjusted for
2012 baseline VBAC rate and country, with random intercept for
site
Odds Ratio 95% CI p-value
OptiBIRTH v Control 0.87 (0.67, 1.14) 0.32
VBAC proportion in 2012 (%) 1.04 (1.02, 1.06) < 0.001
Germany v Ireland 1.09 (0.85, 1.39) 0.49
Italy v Ireland 1.44 (0.98, 2.12) 0.06
ICC for Site = 0.0057
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resulting in an improvement in VBAC rates of even 5%
would be clinically significant.
In Italy, where VBAC rates in intervention and control
sites were lower pre-trial (8.3 and 10.6%) compared with
Ireland and Germany (32.1 and 22.2%, and 33.7 and
27.3%), VBAC rates increased to a greater extent. The
overall VBAC rate rose in intervention sites in Italy from
8.3% in 2012, to 19.6% in 2016, the year after the trial.
Thus, in countries or sites where VBAC rates are very
low, the OptiBIRTH intervention may be more effective
within a relatively shorter time frame. The VBAC rate in
control sites in Italy also rose from 10.6 to 21.3% in the
same time, which may be due to the Hawthorne effect
where being involved in the study, even in the control
group, may have encouraged clinicians to review their
practice, and offer VBAC rather than elective repeat CS.
In addition, the control sites were offered the interven-
tion in 2016, once the trial was complete, which may
have assisted them to change.
Secondary outcomes were compared using the birthing
data available for women who agreed to join the trial
(intervention: 1174; control: 782). There was a statisti-
cally significant absolute increase of 4.3% in the VBAC
rate (95% CI: 0 to 9%) (32.8% in the intervention group,
Table 6 Mode of birth for the 1940 recruited women with known mode of birth
Mode of birth Country Intervention sites Control sites Risk ratio
[95% CI]
All births Trial as a whole 1165 775
Germany 458 280
Ireland 361 249
Italy 346 246
VBAC (% of births) Trial as a whole 385 (33.0) 223 (28.8) 1.16 [1.01, 1.33]
Germany 179 (39.1) 113 (40.4) 1.00 [0.84, 1.20]
Ireland 125 (34.6) 65 (26.1) 1.34 [1.04, 1.74]
Italy 81 (23.4) 45 (18.3) 1.31 [0.93, 1.84]
Spontaneous vaginal (% of births) Trial as a whole 306 (26.3) 170 (21.9) 1.22 [1.04, 1.44]
Germany 150 (32.8) 92 (32.9) 1.06 [0.86, 1.31]
Ireland 84 (23.3) 38 (15.3) 1.52 [1.07, 2.15]
Italy 72 (20.8) 40 (16.3) 1.31 [0.91, 1.90]
Ventouse (% of births) Trial as a whole 78 (6.7) 47 (6.1) 1.08 [0.76, 1.53]
Germany 29 (6.3) 21 (7.5) 0.77 [0.45, 1.32]
Ireland 40 (11.1) 21 (8.4) 1.38 [0.82, 2.34]
Italy 9 (2.6) 5 (2.0) 1.28 [0.42, 3.90]
Forceps (% of births) Trial as a whole 1 (0.1) 6 (0.8) 0.16 [0.03, 0.99]
Germany 0 (0) 0 (0) No data
Ireland 1 (0.3) 6 (2.4) 0.16 [0.03, 0.99]
Italy 0 (0) 0 (0) No data
Elective CS (% of births) Trial as a whole 504 (43.3) 393 (50.7) 0.85 [0.77, 0.93]
Germany 178 (38.9) 98 (35.0) 1.05 [0.85, 1.30]
Ireland 119 (33.0) 131 (52.6) 0.65 [0.54, 0.78]
Italy 207 (59.8) 164 (66.7) 0.89 [0.78, 1.00]
Emergency CS (not in labour) (% of births) Trial as a whole 141 (12.1) 57 (7.4) 1.64 [1.22, 2.21]
Germany 41 (9.0) 13 (4.6) 1.88 [1.02, 3.46]
Ireland 61 (16.9) 17 (6.8) 2.27 [1.35, 3.83]
Italy 39 (11.3) 27 (11.0) 1.10 [0.70, 1.74]
Emergency CS (in labour) (% of births) Trial as a whole 135 (11.6) 102 (13.2) 0.88 [0.68, 1.13]
Germany 60 (13.1) 56 (20.0) 0.69 [0.48, 0.98]
Ireland 56 (15.5) 36 (14.5) 1.07 [0.70, 1.64]
Italy 19 (5.5) 10 (4.1) 1.27 [0.61, 2.66]
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28.5% in control) (RR: 1.16; 95% CI: 1.01 to 1.33; p =
0.03). However, when this was adjusted for baseline
characteristics, the difference was no longer statistically
significant. No differences were seen in rates of induc-
tion or acceleration of labour between the two groups.
This increase in VBAC among women who took part in
the intervention may indicate that the intervention needs
to be encouraged across the board, with both clinicians
and women taking part to ensure any change in practice.
A break-down of the results shows apparent anomalies
in some countries. For example, in the intervention sites
in Ireland there was an overall drop in VBAC rates from
32.1% (2012) to 25.6% (2016), while the data from women
participating in the trial in those sites showed a VBAC
rate of 34.2%. This suggests that the VBAC rate for
women not in the trial in 2016 was much lower than the
2012 norm. Evidence to support this comes from the drop
in VBAC rates between 2012 and 2016 occurring, for
some reason, in one of the three Irish intervention sites
only. Recent work on VBAC rates in two of the largest
maternity hospitals in Ireland corroborates this evidence,
showing a steep decline from 64.4% in 1990 to 32.9% in
2014, with rates still falling from 2012 to 2014 [32]. Simi-
lar decreases were also shown in Massachusetts, from 32%
to below 10% for the decade 2000 to 2010, and in one area
of Germany, which showed a decrease from 48% in 1990
to around 25% in 2012 [32]. These decreases may be a re-
action to the publication of a number of studies in the late
1990s and early 2000s that highlighted the risks of VBAC,
without taking account of the international consensus that
VBAC, using evidence-based guidelines, is a clinically safe
choice for most women with a previous CS [32]. The de-
crease in VBAC rates in the Irish intervention sites over
the time-period of the OptiBIRTH study (2012 to 2016)
may also have been affected by many adverse reports in
the Irish media, including an investigation into maternity
care practices at one of the participating sites and, in par-
ticular, one situation where a maternity hospital sought a
Fig. 3 VBAC for the recruited women with data on mode of birth, by randomised comparison, within countries and overall
Table 7 Spontaneous onset of labour for the recruited women
who went into labour
Mode of birth Country Intervention
sites
Control
sites
Risk ratio
[95% CI]
Spontaneous onset
of labour (% of women
who went into labour)
Trial as a
whole
445 (84.4) 281
(85.2)
0.99
[0.93,
1.05]
Germany 185 (77.1) 136
(79.5)
0.98
[0.88,
1.08]
Ireland 157 (86.3) 92
(89.3)
0.96
[0.87,
1.06]
Italy 103 (98.1) 53
(94.6)
1.04
[0.97,
1.11]
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court order (unsuccessfully) to compel a woman to have a
CS [33]. Due to the use of a cluster randomised trial
methodology, the intervention could not be changed or
modified to suit either different countries or altered cir-
cumstances in one country during the study. Using an im-
plementation science approach might have allowed
researchers and clinicians to modify the educational inter-
vention in response to changing conditions.
Elective CS differed between the two groups (42.9% in
intervention and 50.3% in control), perhaps indicating that
the intervention had some effect in supporting women
and clinicians in deciding to plan a VBAC. However, there
was an increase in the rate of unplanned CS prior to
labour in the intervention group (12% compared to 7.3%),
which may have indicated a change of mind, or the emer-
gence of clinical factors preventing a planned VBAC.
As 75% of all women entering labour and planning a
VBAC in this study, had a successful VBAC, the avoid-
ance of elective CS is key in increasing VBAC rates [34].
In terms of safety, there were two full uterine ruptures
Table 8 Labour and birth outcomes for the recruited women, by subgroups
Outcome Subgroup (relevant births in intervention;
control groups)
Intervention Control Risk ratio [95% CI]
VBAC (% of all births with known
mode of birth that were VBAC)a
Trial as a whole (1165; 775) 385 (33.0) 223 (28.8) 1.16 [1.01, 1.33]
Germany (458; 280) 179 (39.1) 113 (40.4) 1.00 [0.84, 1.20]
Ireland (361; 241) 125 (34.6) 65 (26.1) 1.34 [1.04, 1.74]
Italy (346; 246) 81 (23.4) 45 (18.3) 1.31 [0.93, 1.84]
Vaginal birth before previous CS (104; 54) 51 (49.0) 26 (48.1) 0.99 [0.70, 1.40]
No vaginal births before previous CS (1061; 721) 334 (31.5) 197 (27.3) 1.17 [1.01, 1.36]
Prior VBAC (74; 32) 54 (73.0) 25 (78.1) 0.98 [0.77, 1.25]
No prior VBAC (1091; 743) 331 (30.3) 198 (26.6) 1.15 [0.99, 1.34]
Recruitment at < 30 weeks (621; 459) 178 (28.7) 123 (26.8) 1.14 [0.92, 1.41]
Recruitment at 30–32 weeks (104; 44) 28 (26.9) 15 (34.1) 0.65 [0.38, 1.11]
Recruitment at ≥33 weeks (438; 270) 178 (40.6) 85 (31.5) 1.21 [0.99, 1.48]
BMI (< 25.00) (555; 307) 208 (37.5) 113 (36.8) 1.06 [0.89, 1.26]
BMI (25–29.99) (347; 268) 103 (29.7) 72 (26.9) 1.06 [0.81, 1.38]
BMI (> 29.99) (201; 175) 52 (25.9) 33 (18.9) 1.34 [0.91, 1.96]
Age (< 40 years) (1074; 701) 354 (33.0) 210 (30.0) 1.11 [0.97, 1.28]
Age (≥40 years) (91; 71) 31 (34.1) 13 (18.3) 1.96 [1.10, 3.49]
Spontaneous onset of labour (% of all women
who went into labour who had a spontaneous
onset of labour)b
Trial as a whole (527; 330) 445 (84.4) 281 (85.2) 0.99 [0.93, 1.05]
Germany (240; 171) 185 (77.1) 136 (79.5) 0.98 [0.88, 1.08]
Ireland (182; 103) 157 (86.3) 92 (89.3) 0.96 [0.87, 1.06]
Italy (105; 56) 103 (98.1) 53 (94.6) 1.04 [0.97, 1.11]
Vaginal birth before previous CS (57; 50) 50 (87.7) 24 (80.0) 1.07 [0.83, 1.38]
No vaginal births before previous CS (470; 300) 395 (84.0) 257 (85.7) 0.98 [0.92, 1.04]
Prior VBAC (56; 29) 44 (78.6) 21 (72.4) 1.02 [0.78, 1.32]
No prior VBAC (471; 301) 401 (85.1) 260 (86.4) 0.98 [0.92, 1.04]
Recruitment at < 30 weeks (255; 186) 226 (88.6) 161 (86.6) 1.01 [0.92, 1.09]
Recruitment at 30–32 weeks (42; 22) 33 (78.6) 19 (86.4) 0.97 [0.73, 1.30]
Recruitment at ≥33 weeks (229; 122) 186 (81.2) 101 (82.8) 0.98 [0.88, 1.08]
BMI (< 25.00) (277; 158) 237 (85.6) 137 (86.7) 0.99 [0.91, 1.08]
BMI (25–29.99) (151; 106) 127 (84.1) 90 (84.9) 0.97 [0.86, 1.09]
BMI (> 29.99) (76; 57) 60 (78.9) 46 (80.7) 0.95 [0.78, 1.14]
Age (< 40 years) (489; 311) 414 (84.7) 265 (85.2) 0.99 [0.93, 1.05]
Age (≥40 years) (38; 19) 31 (81.6) 16 (84.2) 1.04 [0.82, 1.31]
a. The following data are missing for women who gave birth: gestational age at baseline is missing for 1 women (intervention), BMI at baseline is missing for 27
women (intervention: 22; control: 5)
b. The following data are missing for women who went into labour: BMI at baseline is missing for 29 women (intervention: 21; control: 8)
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in the main OptiBIRTH trial (one in each group), a rate
of 1 per 1000, which is lower than the published rate of
2.1 per 1000 maternities previously identified [35]. Intra-
uterine and neonatal death rates showed no difference
between intervention and control groups, and were
equivalent to or below the lowest quoted European rates
[36]. Other neonatal outcomes examined (admission to
NICU, and preterm birth) also did not differ significantly
between the two groups. Separate economic analysis
showed that VBAC resulted in a cost reduction ranging
from €3,334,052 (Germany) to €66,162,379 (Ireland) and
gains in quality-adjusted life-years from 6399 (Italy) to
7561 (Germany) per 100,000 women birthing in each
country [37].
Limitations of the OptiBIRTH cluster trial include
missing data from 46 of the 2002 recruited women who
moved away, or gave birth in another maternity unit
(2.3%). The heterogeneity seen in the various sites is also
an unavoidable issue in cluster randomised trials, and is
a reality in ‘real world’ research.
The results of this trial may not be generalisable, be-
cause other settings, with different participants, fewer or
more resources, differing extents of training or motivation
of healthcare professionals and more positive or negative
media foci, could produce different results. In this study,
in settings with high rates of repeat CS for women with
one previous CS, clinicians and women alike may view re-
peat CS as usual and beneficial. However, our economic
analysis showed that women who expressed a preference
for a vaginal birth, but who gave birth by elective repeat
caesarean section, had impaired health-related quality of
life at 3 months postnatal [38]. Belief in increased rates of
uterine rupture with planned VBAC, and exaggerated
fears of the ensuing complications [39] thus should not
prevent clinicians from offering, and supporting women
to achieve, VBAC within the context of genuine shared
decision-making [40]. Providing the OptiBIRTH interven-
tion in other settings could produce different results,
especially if time is spent informing clinicians and policy-
makers of these results, and the safety of the intervention,
Table 9 Antenatal and neonatal outcomes
Outcome Country (recruited women relevant
to each subgroup with birth data
available in intervention; control groups)
Intervention sites Control sites Risk ratio [95% CI] or
Mean Difference [95% CI]
Intrauterine death before 24 weeks
(% with birthing data)
Trial as a whole (1174; 782) 7 (0.6) 3 (0.4) 1.22 [0.36, 4.11]
Germany (458; 282) 0 (0.0) 1 (0.4) 0.38 [0.02, 9.27]
Ireland (365; 250) 6 (1.6) 0 (0) 6.45 [0.37, 113.52]
Italy (351; 250) 1 (0.3) 2 (0.8) 0.50 [0.07, 3.36]
Intrauterine death after 24 weeks
(% with birthing data)
Trial as a whole (1174; 782) 4 (0.2) 2 (0.2) 1.16 [0.28, 4.83]
Germany (458; 282) 1 (0.2) 1 (0.4) 0.66 [0.08, 5.78]
Ireland (365; 250) 1 (0.3) 1 (0.4) 1.08 [0.07, 17.15]
Italy (351; 250) 2 (0.6) 0 (0) 2.97 [0.14, 61.50]
Neonatal death (% of live-born) Trial as a whole (1163; 777) 0 (0) 2 (0.3) 0.26 [0.03, 2.34]
Germany (457; 280) 0 (0) 1 (0.4) 0.38 [0.02, 9.15]
Ireland (358; 249) 0 (0) 1 (0.4) 0.17 [0.01, 4.13]
Italy (348; 248) 0 (0) 0 (0) No data
Live-born before 37 weeks
(% of live-born)a
Trial as a whole (1163; 777) 62 (5.3) 50 (6.4) 0.81 [0.56, 1.17]
Germany (457; 280) 18 (3.9) 16 (5.7) 0.61 [0.31, 1.21]
Ireland (358; 249) 19 (5.3) 10 (4.0) 1.23 [0.59, 2.56]
Italy (348; 248) 25 (7.2) 24 (9.7) 0.77 [0.45, 1.32]
Gestational age at live birth (mean, SD)a Trial as a whole (1163; 777) 38.9 (1.5) 38.7 (1.8) 0.15 [0.00, 0.30]
Germany (457; 280) 38.9 (1.4) 39.0 (1.8) −0.10 [−0.35, 0.15]
Ireland (358; 249) 39.1 (1.5) 39.0 (1.7) 0.10 [−0.16, 0.36]
Italy (348; 248) 38.6 (1.7) 38.1 (1.6) 0.50 [0.23, 0.77]
Admission to NICU (% of live-born) Trial as a whole (1163; 777) 90 (7.7) 63 (8.1) 0.87 [0.64, 1.17]
Germany (457; 280) 34 (7.4) 28 (10.0) 0.58 [0.35, 0.95]
Ireland (358; 249) 40 (11.2) 28 (11.2) 0.97 [0.62, 1.51]
Italy (348; 248) 16 (4.6) 7 (2.8) 1.70 [0.73, 3.93]
1. Gestational age at birth is missing for 56 live-born infants (intervention: 25; control: 31)
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Table 10 Neonatal outcomes, by subgroups
Outcome Subgroup (recruited women relevant
to each subgroup with baby data
available in intervention; control groups)
Intervention Control Risk ratio [95% CI] or
Mean Difference [95% CI]
Live-born before 37 weeks (% of live-born)a Trial as a whole (1163; 777) 62 (5.3) 50 (6.4) 0.81 [0.56, 1.17]
Germany (457; 280) 18 (3.9) 16 (5.7) 0.61 [0.31, 1.21]
Ireland (358; 249) 19 (5.3) 10 (4.0) 1.23 [0.59, 2.56]
Italy (348; 248) 25 (7.2) 24 (9.7) 0.77 [0.45, 1.32]
Vaginal birth before previous CS (104; 54) 8 (7.7) 7 (13.0) 0.67 [0.26, 1.71]
No vaginal births before previous CS (1059; 723) 54 (5.1) 43 (5.9) 0.83 [0.56, 1.24]
Prior VBAC (74; 32) 3 (4.1) 1 (3.1) 0.87 [0.13, 6.02]
No prior VBAC (1089; 745) 59 (5.4) 49 (6.6) 0.81 [0.56, 1.17]
Recruitment at < 30 weeks (619; 461) 44 (7.1) 31 (6.7) 0.98 [0.62, 1.56]
Recruitment at 30–32 weeks (104; 44) 7 (6.7) 5 (11.4) 0.73 [0.26, 2.11]
Recruitment at ≥33 weeks (438; 270) 11 (2.5) 13 (4.8) 0.51 [0.24, 1.10]
BMI (< 25.00) (553; 309) 25 (4.5) 21 (6.8) 0.64 [0.37, 1.11]
BMI (25–29.99) (347; 268) 23 (6.6) 15 (5.6) 1.19 [0.61, 2.33]
BMI (> 29.99) (202; 175) 10 (5.0) 14 (8.0) 0.77 [0.34, 1.77]
Age (< 40 years) (1072; 702) 55 (5.1) 40 (5.7) 0.88 [0.59, 1.32]
Age (≥40 years) (91; 72) 7 (7.7) 9 (12.5) 0.63 [0.26, 1.52]
Gestational age at birth (mean, SD)b Trial as a whole (1163; 777) 38.9 (1.5) 38.7 (1.8) 0.15 [0.00, 0.30]
Germany (457; 280) 38.9 (1.4) 39.0 (1.8) −0.10 [−0.35, 0.15]
Ireland (358; 249) 39.1 (1.5) 39.0 (1.7) 0.10 [−0.16, 0.36]
Italy (348; 248) 38.6 (1.7) 38.1 (1.6) 0.50 [0.23, 0.77]
Vaginal birth before previous CS (104; 54) 38.7 (1.9) 38.4 (2.0) 0.30 [−0.35, 0.95]
No vaginal births before previous CS (1059; 723) 38.9 (1.5) 38.7 (1.7) 0.20 [0.05, 0.35]
Prior VBAC (74; 32) 39.0 (1.5) 39.4 (1.4) −0.40 [−0.99, 0.19]
No prior VBAC (1089; 745) 38.9 (1.6) 38.7 (1.8) 0.20 [0.04, 0.36]
Recruitment at < 30 weeks (619; 461) 38.7 (1.7) 38.7 (1.8) 0.00 [−0.21, 0.21]
Recruitment at 30–32 weeks (104; 44) 38.7 (1.5) 38.3 (1.9) 0.40 [−0.23, 1.03]
Recruitment at ≥33 weeks (438; 270) 39.1 (1.3) 38.9 (1.5) 0.20 [−0.02, 0.42]
BMI (< 25.00) (553; 309) 38.9 (1.5) 38.8 (1.7) 0.10 [−0.13, 0.33]
BMI (25–29.99) (347; 268) 38.9 (1.6) 38.7 (1.7) 0.20 [−0.06, 0.46]
BMI (> 29.99) (202; 175) 38.8 (1.5) 38.5 (1.9) 0.30 [−0.05, 0.65]
Age (< 40 years) (1072; 702) 38.9 (1.6) 38.8 (1.7) 0.10 [−0.06, 0.26]
Age (≥40 years) (91; 72) 38.6 (1.5) 38.3 (1.8) 0.30 [−0.22, 0.82]
Admission to NICU (% of live-born)c Trial as a whole (1163; 777) 90 (7.7) 63 (8.1) 0.87 [0.64, 1.17]
Germany (457; 280) 34 (7.4) 28 (10.0) 0.58 [0.35, 0.95]
Ireland (358; 249) 40 (11.2) 28 (11.2) 0.97 [0.62, 1.51]
Italy (348; 248) 16 (4.6) 7 (2.8) 1.70 [0.73, 3.93]
Vaginal birth before previous CS (104; 54) 11 (10.6) 6 (11.1) 0.97 [0.43, 2.21]
No vaginal births before previous CS (1059; 723) 79 (7.5) 57 (7.9) 0.85 [0.62, 1.18]
Prior VBAC (74; 32) 8 (10.8) 4 (12.5) 0.93 [0.34, 2.58]
No prior VBAC (1089; 745) 82 (7.5) 59 (7.9) 0.87 [0.64, 1.20]
Recruitment at < 30 weeks (619; 462) 60 (9.7) 40 (8.7) 1.08 [0.74, 1.58]
Recruitment at 30–32 weeks (104; 44) 6 (5.8) 4 (9.1) 0.68 [0.22, 2.11]
Recruitment at ≥33 weeks (438; 270) 23 (5.3) 19 (7.0) 0.63 [0.36, 1.11]
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when applied as it was in this study. The qualitative as-
pects of this study showed clearly that a national culture
that supports VBAC, and care in pregnancy and labour
from confident and supportive clinicians are essential for
success [41]. In particular, using an implementation re-
search approach to introduce evidence-based interven-
tions could be much more beneficial in that clinicians
would be helped to identify and resolve existing barriers
to supporting VBAC, and the intervention could be tai-
lored to suit each site.
In summary, our results showed no significant differ-
ence in adverse maternal or neonatal outcomes between
women exposed to the OptiBIRTH intervention and
those who were not. There was no statistically significant
difference in the change in the proportion of women
having a VBAC between intervention and control sites.
At individual site level, however, the results appear to
show that the OptiBIRTH intervention may assist in
supporting VBAC in sites with very low VBAC rates. As
elective repeat CS is the most common reason for CS in
multiparous women, and contributes to at least 10% of
all CSs [42], interventions that are feasible and safe, and
that have been shown to lead to a decrease of elective
CS should be promoted. Continued research to refine
the best way of promoting VBAC is essential, and this
may best be done using an implementation science ap-
proach that can modify evidence-based interventions in
response to changing clinical circumstances.
Conclusion
This cluster randomised trial tested the effectiveness of
the OptiBIRTH intervention in 15 sites in three coun-
tries and found no statistically significant difference in
the change in the proportion of women having a VBAC
between the intervention sites and the control sites. Im-
portantly, and in terms of safety, there no differences in
rates of uterine rupture, intra-uterine and neonatal death
rates between intervention and control groups. The pro-
portion of women having a VBAC in intervention sites
with the lowest VBAC rates at the start of the trial rose
by over 11% in the year after the trial concluded. This
may indicate that the OptiBIRTH intervention is more
effective in hospitals or countries with very low VBAC
rates. CSs rates increased and VBAC rates decreased
over time so it should not be surprising that it takes time
to reverse this trend. Our concluding message is that the
OptiBIRTH intervention is feasible and safe. The key
components include an educational intervention pro-
vided by an opinion leader, evidence-based, unbiased in-
formation on the benefits and limitations of VBAC for
women and, importantly, the option to become genuine,
informed decision-makers in their care.
Continued research to refine the best way of promoting
VBAC is essential. This may best be done using an imple-
mentation science approach that can modify evidence-
based interventions, such as OptiBIRTH, in response to
changing clinical circumstances.
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